RecruitingPhase 1NCT07140614
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
Studying Charcot-Marie-Tooth disease type 1A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Intervention
- EDK060, dose A(drug)
- Enrollment
- 28 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2025 – 2028
Study locations (3)
- Novartis Investigative Site, Ottawa, Ontario, Canada
- Montreal Neurological Institute, Montreal, Quebec, Canada
- CIUSS de l´Estrie-CHUS- Hôpital Fleurimont, Sherbrooke, Quebec, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07140614 on ClinicalTrials.govOther trials for Charcot-Marie-Tooth disease type 1A
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07049588Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A DiseaseAssistance Publique Hopitaux De Marseille
- RECRUITINGNCT07476365A Multi-omic Approach to the Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease (CMT1A)University Medical Center Goettingen
- RECRUITINGNCT06794489Longitudinal Biomarkers With Selected Outcome Measures In CMTUniversity Medical Center Goettingen
- ACTIVE NOT RECRUITINGNANCT02596191Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and BiomarkersAssistance Publique Hopitaux De Marseille